Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for enVVeno Medical Corporation (NVNO : NSDQ)

• Company Description    enVVeno Medical Corporation is a medical device company. It focuses in the treatment of venous disease. enVVeno Medical Corporation, formerly known as Hancock Jaffe Laboratories Inc., is based in IRVINE, CA. Number of Employees: 37

• Price / Volume Information    Yesterday's Closing Price: $0.68 Daily Weekly Monthly 20 Day Moving Average: 305,897 shares Shares Outstanding: 20.22 (millions) Market Capitalization: $13.71 (millions) Beta: 0.86 52 Week High: $5.62 52 Week Low: $0.62 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -29.14% -29.59% 12 Week -85.19% -85.91% Year To Date -77.54% -80.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 70 DOPPLER - IRVINE,CA 92618 USA ph: 949-261-2900 fax: 949-261-2992 nvno@jtcir.com https://envveno.com

• General Corporate Information    Officers Robert A. Berman - Director; Chief Executive Officer Craig Glynn - Chief Financial Officer and Treasurer Marc H. Glickman - Senior Vice President and Chief Medical Officer Hamed Alavi - Senior Vice President & Chief Technology Officer Dr. Francis Duhay - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 29415J106 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 20.22 Most Recent Split Date: 11.00 (0.04:1) Beta: 0.86 Market Capitalization: $13.71 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.08 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.47 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 34.29% vs. Previous Quarter: 30.30% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -61.45 06/30/25 - -57.35 03/31/25 - -51.32 ROA 09/30/25 - -56.88 06/30/25 - -53.49 03/31/25 - -48.23 Current Ratio 09/30/25 - 13.12 06/30/25 - 11.81 03/31/25 - 23.77 Quick Ratio 09/30/25 - 13.12 06/30/25 - 11.81 03/31/25 - 23.77 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 1.46 06/30/25 - 1.72 03/31/25 - 2.18 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©